Blog
RSS FeedPosted by Michael Wonder on 01 May 2016
Schedule of Pharmaceutical Benefits - 1 May 2016 update
1 May 2016 - The May 2016 issue of the Schedule sees a number of new and revised listings. ...
Posted by Michael Wonder on 30 Apr 2016
New Zealand Pharmaceutical Schedule - 1 May 2016 update
1 May 2016 - The May 2016 update to the New Zealand Pharmaceutical Schedule sees the listing of two new medicines. ...
Posted by Michael Wonder on 29 Apr 2016
PBS listing of tamoxifen citrate projected to benefit thousands of women
29 April 2016 - Thousands of women will benefit from subsidised access to the breast cancer drug Tamoxifen which has been ...
Posted by Michael Wonder on 29 Apr 2016
Breakthrough melanoma drug approved
29 April 2016 - A new breakthrough melanoma drug has been approved for use in New Zealand, but like its rival ...
Posted by Michael Wonder on 29 Apr 2016
Productivity Commission draft report on intellectual property arrangements
29 April 2016 - Medicines Australia notes the release of the draft report from the Productivity Commission concerning Australia’s Intellectual Property ...
Posted by Michael Wonder on 29 Apr 2016
NICE recommends combined drug therapy proven to extend life for skin cancer
29 April 2016 - NICE is today recommending a new drug combination for melanoma that could extend life by six months. ...
Posted by Michael Wonder on 29 Apr 2016
PBS and RPBS Section 85 date of processing and date of supply data
29 April 2016 - The PBS and RPBS Section 85 date of processing and date of supply data has now been ...
Posted by Michael Wonder on 28 Apr 2016
Big pharma gaming patents for extra cash: Productivity Commission
29 April 2016 - Global pharmaceutical giants are boosting revenues by unnecessarily extending patents in Australia, which is also slowing access ...
Posted by Michael Wonder on 28 Apr 2016
Anti-cancer drug Ribomustin added to PBS
28 April 2016 - Up to 30,000 Australians living with a slow-growing form of lymphoma could benefit from a new anti-cancer ...
Posted by Michael Wonder on 28 Apr 2016
Agenda for the July 2016 PBAC meeting
28 April 2016 - The agenda for the July 2016 PBAC meeting is now available. ...
Posted by Michael Wonder on 28 Apr 2016
PBAC to consider first submission for a cellular therapy in July
28 April 2016 - The PBAC will consider a major submission from Amgen for talimogene laherparepvec (Imlygic) at its next scheduled ...
Posted by Michael Wonder on 27 Apr 2016
bDMARDs on the PBS – are they all the same?
28 April 2016 - Adalimumab (Humira) has been listed on the Pharmaceutical Benefits Scheme (PBS) since 2004 for use by certain ...
Posted by Michael Wonder on 27 Apr 2016
NICE & PBAC outcomes differ for new heart failure drug Entresto
27 April 2016 - Around 100,000 people in England and Wales could now benefit from treatment with Novartis’ revolutionary heart failure ...
Posted by Michael Wonder on 27 Apr 2016
Medicines New Zealand has never threatened New Zealand
26 April 2016 - Recent statements in the media misrepresent the Medicines New Zealand position on the Trans-Pacific Partnership and are ...
Posted by Michael Wonder on 27 Apr 2016
NICE recommends ovarian cancer treatments
27 April 2016 - NICE has published final guidance for five ovarian cancer drugs. Three of the drugs are not recommended, ...